NASHVILLE, Tenn., Oct. 25,
2023 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX)
("Cryoport" or the "Company"), a leading global provider of
innovative products and services to the fast-growing cell and gene
therapy industry enabling the future of medicine for a new era of
life sciences, today announced that the Company will report
financial results for the third quarter ended September 30, 2023 on Wednesday, November 8, 2023 after U.S. markets
close.
In addition to the earnings release, a document titled "Cryoport
Third Quarter 2023 in Review", providing a review of Cryoport's
financial and operational performance and a general business
update, will be issued at 4:05 p.m. ET on Wednesday, November 8, 2023. The document is
designed to be read in advance of the questions and answers
conference call and will be accessible at
http://ir.cryoport.com/events-and-presentations.
Cryoport management will host a conference call the same day at
5:00 p.m. ET. The conference call
will be in the format of a questions and answers session and will
address questions members of the investment community have
regarding the Company's reported results. A slide deck will
accompany the call.
Conference Call Information
Date:
|
Wednesday, November 8,
2023
|
Time:
|
5:00 p.m.
ET
|
Dial-in
numbers:
|
1-888-886-7786 (U.S.),
1-416-764-8658 (International)
|
Confirmation
code:
|
Request the "Cryoport
Call" or Conference ID: 15559162
|
Live webcast:
|
'Investor Relations'
section at www.cryoport.com or click here.
|
|
Please allow 10 minutes
prior to the call to visit this site to download and install any
necessary audio software.
|
The questions and answers call will be recorded and available
approximately three hours after completion of the live event in the
Investor Relations section of the Company's website at
www.cryoport.com for a limited time. To access the replay of
the questions and answers click here. A dial-in replay of the call
will also be available to those interested, until November 15, 2023. To access the replay, dial
1-844-512-2921 (United States) or
1-412-317-6671 (International) and enter replay entry code:
15559162#.
About Cryoport, Inc
Cryoport, Inc. (Nasdaq: CYRX), is
a global provider of innovative products and services to the
fast-growing Cell & Gene Therapy industry - enabling the future
of medicine for a new era of life sciences. With 48 strategic
locations covering the Americas, EMEA (Europe, the Middle
East and Africa) and APAC
(Asia Pacific), Cryoport's global
platform provides mission-critical bio-logistics, bio-storage,
bio-processing, and cryogenic systems to the life sciences markets
worldwide.
For more information, visit www.cryoport.com or follow @cryoport
on X, formerly known as Twitter at www.twitter.com/cryoport for
live updates.
Forward-Looking Statements
Statements in this
press release which are not purely historical, including statements
regarding the Company's intentions, hopes, beliefs, expectations,
representations, projections, plans or predictions of the future,
are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, those related to the
Company's industry, business, long-term growth prospects, including
expected growth in all of the Company's markets, plans, strategies,
acquisitions, future financial results and financial condition,
such as the Company's outlook and guidance for full year 2023
revenue and the related assumptions and factors expected to drive
revenue, projected growth trends in the markets in which the
Company operates, the Company's plans and expectations regarding
the launch of new products and services, such as the expected
timing and benefits of such products and services launches, the
Company's plans to further strengthen its business and continue to
position itself for long-term and profitable growth in the cell and
gene therapy industry, and anticipated regulatory filings or
approvals with respect to the products of the Company's clients. It
is important to note that the Company's actual results could differ
materially from those in any such forward-looking statements.
Factors that could cause actual results to differ materially
include, but are not limited to, risks and uncertainties associated
with the effect of changing economic conditions, including as a
result of the COVID-19 pandemic and its variants, supply chain
constraints, inflationary pressures, the ongoing war between
Russia and Ukraine and the effects of foreign currency
fluctuations, trends in the products markets, variations in the
Company's cash flow, market acceptance risks, and technical
development risks. The Company's business could be affected by a
number of other factors discussed in the Company's SEC reports,
including in the "Risk Factors" section of its most recently filed
periodic reports on Form 10-K and Form 10-Q, as well as in its
subsequent filings with the SEC. The forward-looking statements
contained in this press release speak only as of the date hereof
and the Company cautions investors not to place undue reliance on
these forward-looking statements. Except as required by law, the
Company disclaims any obligation, and does not undertake to update
or revise any forward-looking statements in this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cryoport-to-report-third-quarter-2023-financial-results-on-november-8-2023-301966861.html
SOURCE Cryoport, Inc.